MEDI7510

BIOLOGICAL2 trials

Sponsors

MedImmune LLC

Conditions

Respiratory Syncytial VirusRespiratory Syncytial Virus (RSV)

Phase 1

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

CompletedNCT02289820

MedImmune LLCRespiratory Syncytial Virus (RSV)

Start: 2015-01-05End: 2016-02-24Updated: 2018-03-15

Phase 2

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

TerminatedNCT02508194

MedImmune LLCRespiratory Syncytial Virus

Start: 2015-09-29End: 2016-11-07Updated: 2017-12-26

Related Papers

Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation.

2019-11-2121 citations

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

The Journal of Infectious Diseases2017-09-18128 citations

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

Clinical and Vaccine Immunology2017-07-0634 citations